Sangkeun(SK) Park

Sangkeun (SK) Park has worked in the pharmaceutical industry since 1998. Sangkeun(SK) started their career as an Assistant Product Manager at Pharmacia in 2000, and then worked as a Product Manager at Janssen, Pharmaceutical Companies of Johnson and Johnson in 2003. In 2006, they completed a J&J MBA Internship Program (International) at Johnson & Johnson VisionCare. From 2007 to 2018, they held various roles at The Janssen Pharmaceutical Companies of Johnson & Johnson, including New Product Commercialization & Business Development, Marketing Manager, TA Leader (Dermatology-Immunology), Sr. product manager, Oncology, and Prodcut manager (IRDP). In 2018, they became General Manager, Korea at Actelion. In 2021, they were appointed President, M2N Bio at M2N. Currently, they are Head Of Research And Development, CEO of Sillajen US, where they lead the US subsidiary and all R&D functions including Research Clinical development, R&D strategy and manages Chief Technical offier, Chief Medical officer, Head of reserach, Head of R&D strategy.

Sangkeun(SK) Park obtained a Bachelor of Pharmacy from Chung-Ang University between 1994 and 1998. Sangkeun(SK) then went on to pursue a Master of Business Administration from UNC Kenan-Flagler Business School between 2005 and 2007. Additionally, they hold a Pharmacist certification from the Korean Pharmaceutical Association.